Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Flaherty

Sports Medicine Albany, NY Medical Doctor

NPI 1275792483 CMS profile 285568

1367 Washington Ave, Albany Medical Orthopaedic Administration (2Nd Floor), Albany, NY 12206

Open in the dashboard

General payments

$31,478

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Flaherty of Albany, NY is reported in the CMS Open Payments database as having received $31,478 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,268 26
2024 General $1,302 5
2023 General $1,740 28
2022 General $6,260 13
2021 General $2,902 11
2020 General $7,368 13
2019 General $7,638 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Flaherty
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Michael Flaherty were reported at $4,268. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Michael Flaherty Sports Medicine median Middle half National median
2019 $7,638 $1,176 $199–$4,249 $163
2020 $7,368 $708 $96–$2,890 $114
2021 $2,902 $1,213 $152–$3,994 $132
2022 $6,260 $1,230 $159–$3,998 $149
2023 $1,740 $584 $146–$2,836 $160
2024 $1,302 $628 $163–$3,168 $164
2025 $4,268 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Prodigy Surgical Distribution, Inc. $19,160 34 payments
  2. Arthrex, Inc. $8,983 51 payments
  3. Smith+Nephew, Inc. $1,100 5 payments
  4. Zimmer Biomet Holdings, Inc. $1,042 13 payments
  5. Arcuro Medical Inc $809 1 payment
  6. Miach Orthopaedics, Inc. $177 1 payment
  7. DePuy Synthes Sales Inc. $80 2 payments
  8. Pacira Pharmaceuticals Incorporated $64 2 payments
  9. Stryker Corporation $63 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $14,374 28 payments
  2. Education $11,820 12 payments
  3. Food and Beverage $5,285 71 payments
Products named General payments · program years 2019–2025
  1. Q-Fix $1,100 5 payments
  2. Bioraptor Knotless $873 2 payments
  3. SPEEDLOCK HIP $873 2 payments
  4. Suturefix $873 2 payments
  5. ACCUPASS DIRECT Crescent XL $873 2 payments
  6. SUPERBALL $809 1 payment
  7. Comprehensive Shoulder System $231 2 payments
  8. Osteoraptor $200 2 payments
  9. Coblation Wands $200 2 payments
  10. Tricera Handpiece $163 2 payments
  11. Other $1,478 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Orthopedic Surgery: 203

Drug cost

$67

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclobenzaprine Hcl Generic 14 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$57,513

Of which drugs: $185

Medicare patients

189

Average age 71

Services billed

807

105 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 63%
Ischemic heart disease 31%
Diabetes 15%
Cancer 15%
Depression 14%
Chronic kidney disease 13%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 49 248 $185

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record